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Hypertrophic Cardiomyopathy 
Definition and evaluation. Hypertrophic cardiomyo•
pathy, although a relatively uncommon cardiac malforma•
tion, is an important cause of sudden death in young indi•
viduals (1-6), including asymptomatic competitive athletes 
(7). It is a primary disease of cardiac muscle in which the 
essential diagnostic feature is a hypertrophied, nondilated 
left ventricle in the absence of another cardiac or systemic 
disease that could produce left ventricular hypertrophy (8). 
This disease is usually genetically transmitted (9) and dem•
oristrates a wide vatiety of clinical and morphologic features 
(10-\3). 
It is difficult to establish any single absolute left ven•
tricular wall thickness (as assessed by M-mode and two•
dimensional echocardiography) that is definitively diagnos•
tic of hypertrophic cardiomyopathy. Nevertheless, we re•
gard a ventricular septal or left ven~ricular free wall thick•
ness of 15 mm or more ih an adult athlete (or the equivalent 
in children) as a minimal value for the diagnosis of hyper•
trophic cardiomyopathy. However, a wall thickness of 13 
to 14 mm may place the athlete in an inconclusive diagnostic 
"gray zone;" in such a circumstance it may not be possible 
to definitively distinguish hypertrophic cardiomyopathy from 
the "normal athlete heart," in which the left ventricular 
hypertrophy is "physiol~gic" and not truly pathologic (14). 
In such instances, additional data such as positive familial 
transmission of hypertrophic cardiomyopathy (9) or iden•
tification of other echocardiographic or clinical features of 
the disease (10- \3) should be sought. We also recognize 
that the phenotypic e:tpression of hypertrophic cardio•
myopathy (that is, unexplained left ventricular hypertrophy) 
may be incompletely expressed in young children (less than 
about 18 years of age), and, therefore, full morphologic 
manifestation of the disease may not be clearly evident until 
adolescence or young adulthood (15). 
For the purpose of diagnosis, an athlete with hypertrophic 
cardiomyopathy may be evaluated reliably by noninvasive 
testing utilizing, in particular, echocardiography (combined 
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M -mode and two-dimensional) and 12 lead electrocardi-
0graphy; cardiac catheterization is not required for diag•
nostic purposes. Ambulatory electrocardiography is also of 
value in identifying potentially important arrhythmias (such 
as ventricular tachycardia) in older children and adults who 
are at higher risk for sudden death (16-18); however, the 
absence of such arrhythmias does not necessarily imply a 
benign prognosis (16,17). 
Recommendations. 
I. Patients with hypertrophic cardiomyopathy and any of 
the following cannot participate in any competitive sports: 
a) Marked left ventricular hypertrophy (absolute ven•
tricular wall thickness 2': 20 mm) (4,6). 
b) Evidence of significant obstruction to left ventricular 
outflow under basal conditions, estimated by M-rhode 
echocardiography or measured at cardiac catheter•
ization (>50 mm Hg peak systolic pressure gradient); 
however, this is not meant to imply that patients with 
nonobstructive hypertrophic cardiomyopathy are 
without risk for sudden death. 
c) Important ventricular or atrial arrhythmias on am•
bulatory electrocardiography (for example, ventric•
ular tachycardia, couplets, frequent premature ven•
tricular or atrial contractions, atrial fibrillation or atrial 
tachycardia) (16-18). 
d) History of sudden death in relatives with hypertrophic 
cardiomyopathy, particularly if death occurred before 
40 years of age (19). 
e) History of syncope (5). 
2. Patients without any of these findings may engage in 
some low intensity competitive sports (class I.B). 
3. Patients who have been medically or surgically treated 
have the same restrictions as outlined in the first 
recommendation. 
These recommendations are bas~d largely on published 
data as well as clinical experiences, but also on a "common 
sense" approach to the art of the practice of medicine. For 
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example, it is not possible to ascertain the precise risk that 
a person with hypertrophic cardiomyopathy incurs by par•
ticipating in competitive sports because the data that would 
permit such an assessment are not available. Undoubtedly, 
the magnitude of such a risk would depend on several fac•
tors, including the type and intensity of the athletic activity 
as well as the individual disease state. 
Other Myopericardial Diseases 
Myocarditis. Myocarditis is an acute illness of viral or 
other etiologies that may occasionally cause sudden death 
or chronic cardiac dysfunction. In competitive athletes with 
myocarditis, a convalescent period of about 6 months after 
the onset of clinical manifestations is prudent. Before the 
patient returns to competitive athletic training, ventricular 
function should be assessed noninvasively at rest and after 
exertion (with radionuclide angiography or echocardiog•
raphy) and recommendations regarding future activity level 
should be made based on the test results. An athlete will 
be allowed to return to competition only if the 12 lead 
electrocardiogram has returned to normal and there is normal 
ventricular function (at rest and during exercise) and absence 
of clinically significant arrhythmias (repetitive forms of ven•
tricular ectopic activity or sustained supraventricular tachy•
cardia). Such an overall assessment may be achieved 
adequately with maximal exercise testing, 12 lead 
electrocardiography, radionuclide angiography, echocardi•
ography and ambulatory electrocardiographic monitoring. 
Persistence of ventricular dilation, impaired contractility or 
significant arrhythmias would necessitate total or partial re•
striction from athletic competition. 
Pericarditis. Athletes with pericarditis, regardless of 
etiology, should not participate in competitive sports during 
their acute episode. They can return to full activity when 
there is no evidence of active disease by history or physical 
examination, appropriate blood tests, exercise testing and 
ambulatory or 12 lead electrocardiography. In athletes with 
a history of pericarditis associated with evidence of signif•
icant myocardial involvement, recommendations should be 
based on the course of their myocarditis. Athletes with chronic 
pericardial disease that results in constriction should not 
participate in any competitive sports. 
Other myocardial diseases. These conditions of either 
the right or left ventricle include primary dilated cardio•
myopathy (20-22), restrictive nondilated cardiomyopathies 
such as endomyocardial fibrosis with or without eosinopilia 
(23), systemic diseases with cardiac involvement such as 
sarcoidosis (24) and the right ventricular dysplasia syn•
drome (25). Athletes with these diseases, which are all 
potential causes of sudden death, cannot participate in any 
competitive sports. 
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Mitral Valve Prolapse 
Definition and evaluation. Mitral valve prolapse is of 
particular concern because of its high prevalence in the 
general population (about 5%) (26). It is a generally benign 
disorder, characterized by systolic protrusion of the mitral 
valve leaflets into the left atrium (as demonstrated by echo•
cardiography, angiography and pathologic studies [26-30]). 
A mid-systolic (nonejection) click with or without a late 
systolic murmur is the auscultatory hallmark of this syn•
drome (26-28), In some patients with echocardiographic 
evidence of mitral prolapse no auscultatory abnormalities 
are detected despite adequate and repeated examination (26); 
this "silent" form may represent a normal variant in which 
the mitral valve is free of significant morphologic abnor•
malities (28). The detection of a late systolic or pansystolic 
regurgitant murmur or the clear demonstration of valve 
thickening or redundancy with echocardiography indicates 
a structural mitral valve abnormality. In some individuals 
mitral valve prolapse is associated with atypical chest pain, 
palpitation, dizziness, abnormal electrocardiogram and ar•
rhythmias (26,28,31). 
In the diagnosis of mitral valve prolapse, auscultation 
may be supplemented by noninvasive tests such as M-mode, 
two-dimensional and Doppler echocardiography. Ambula•
tory electrocardiography and exercise testing are useful in 
evaluating those patients with symptoms suggestive of ar•
rhythmias (26,28). 
Although sudden death has been reported (32-37) in 
patients with mitral valve prolapse, such occurrences appear 
to be exceedingly rare. To date, only three patients have 
been reported to have died suddenly during exercise (32,34,35) 
and just one of these was a trained competitive athlete (35). 
Recommendations. 
1, Patients with mitral valve prolapse and the following 
criteria may participate only in low intensity competitive 
sports (class I.B): 
a) History of syncope. 
b) Family history of sudden death due to mitral valve 
prolapse. 
c) Chest pain that is worsened by exercise. 
d) Repetitive forms of ventricular ectopic actIVIty or 
sustained supraventricular tachycardia, particularly if 
they are worsened by exercise. 
e) Moderate or marked mitral regurgitation. 
f) Associated dilation of the ascending aorta, in those 
rare instances when mitral valve prolapse and the 
Marfan syndrome are associated. 
2. Patients without any of these findings may engage in all 
competitive sports. 
Based on the overall available clinical evidence, which 
indicates a favorable prognosis for individuals with mitral 
lACC Vol. 6, NO.6 
December 1985: 1215-7 
valve prolapse (26,27,29,30) and a lack of occurrence of 
complications with strenuous activity, this syndrome is viewed 
as a benign cardiac abnormality in the vast majority of 
instances, 
Recommendations regarding the eligibility of athletes with 
mitral valve prolapse syndrome for competition were for•
mulated based on available information, even though natural 
history data in the athlete with mitral prolapse are largely 
lacking; furthermore, considerable controversy continues to 
surround the general clinical significance of the mitral valve 
prolapse syndrome (38), 
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